Ursula La Rocca, Roberto Ricci, Alfonso Piciocchi, Walter Barberi, Elena Oldani, Alida Dominietto, Raffaella Cerretti, Alessandra Picardi, Francesca Bonifazi, Riccardo Saccardi, Maura Faraci, Giovanni Grillo, Lucia Farina, Benedetto Bruno, Anna Grassi, Anna Proia, Elena Tagliaferri, Giuseppina De Simone, Michele Malagola, Michela Cerno, Simone Cesaro, Paolo Bernasconi, Lucia Prezioso, Paola Carluccio, Nicola Mordini, Matteo Pelosini, Attilio Olivieri, Patrizia Chiusolo, Stella Santarone, Michele Cimminiello, Roberto Crocchiolo, Franco Papola, Gianni Rombolà, Nicoletta Sacchi, Valeria Miotti, Lia Mele, Benedetta Mazzi, Fabio Ciceri, Massimo Martino, Anna Paola Iori
{"title":"异体造血干细胞移植患者的供体特异性抗hla抗体（dsa）","authors":"Ursula La Rocca, Roberto Ricci, Alfonso Piciocchi, Walter Barberi, Elena Oldani, Alida Dominietto, Raffaella Cerretti, Alessandra Picardi, Francesca Bonifazi, Riccardo Saccardi, Maura Faraci, Giovanni Grillo, Lucia Farina, Benedetto Bruno, Anna Grassi, Anna Proia, Elena Tagliaferri, Giuseppina De Simone, Michele Malagola, Michela Cerno, Simone Cesaro, Paolo Bernasconi, Lucia Prezioso, Paola Carluccio, Nicola Mordini, Matteo Pelosini, Attilio Olivieri, Patrizia Chiusolo, Stella Santarone, Michele Cimminiello, Roberto Crocchiolo, Franco Papola, Gianni Rombolà, Nicoletta Sacchi, Valeria Miotti, Lia Mele, Benedetta Mazzi, Fabio Ciceri, Massimo Martino, Anna Paola Iori","doi":"10.2450/BloodTransfus.790","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antibodies directed against donor-specific HLA allele(s)/antigen(s) (DSAs) represent a known risk factor for hematopoietic stem cell transplantation (HSCT) engraftment. Still, the overall management needs to be standardized.</p><p><strong>Material and methods: </strong>GITMO and AIBT ran a survey on DSAs in Italian Transplant Programs including mismatched HSCT performed between January 2014 and June 2017.</p><p><strong>Results: </strong>One-thousand-thirty-three patients were proposed for the study, 804 were evaluable. Overall, 355 (44%) were screened: 91/355 (25.6%) showed anti-HLA antibodies, 23 DSAs (6.5%). Female gender and at least 4 previous pregnancies showed an impact on alloimmunization. Eleven patients with DSAs underwent desensitization. In seven cases no desensitization was employed. An alternative donor was selected for five patients. Neutrophil and platelet engraftment were obtained in 93.6% and 86.6% of the whole population, respectively, and were statistically associated with the absence of anti-HLA antibodies, ABO match, a higher number of infused nucleated cells and lack of a-GvHD. In addition, significant factors for platelet engraftment were the use of leuco-depleted transfusions, HLA match, younger age of the patient. Graft failure (GF) was associated with bone marrow stem cell source, and a lower number of infused CD34+. The detection of antibodies directed against both HLA classes, donor and patient age, the hematologic and molecular remission at HSCT, HLA match, ANC and PLTS engraftment, full donor engraftment within 28 days after HSCT, early and late GF, grade>II a-GVHD showed an impact on OS.</p><p><strong>Discussion: </strong>Anti-HLA antibodies and DSAs were confirmed as risk factors affecting OS. DSAs were managed with various approaches resulting in stable engraftment in 81.9% of patients. Our study supports the clinical relevance of DSAs detection and management in mmHSCT. A standardized approach of DS is warranted.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"176-185"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925252/pdf/","citationCount":"0","resultStr":"{\"title\":\"Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT.\",\"authors\":\"Ursula La Rocca, Roberto Ricci, Alfonso Piciocchi, Walter Barberi, Elena Oldani, Alida Dominietto, Raffaella Cerretti, Alessandra Picardi, Francesca Bonifazi, Riccardo Saccardi, Maura Faraci, Giovanni Grillo, Lucia Farina, Benedetto Bruno, Anna Grassi, Anna Proia, Elena Tagliaferri, Giuseppina De Simone, Michele Malagola, Michela Cerno, Simone Cesaro, Paolo Bernasconi, Lucia Prezioso, Paola Carluccio, Nicola Mordini, Matteo Pelosini, Attilio Olivieri, Patrizia Chiusolo, Stella Santarone, Michele Cimminiello, Roberto Crocchiolo, Franco Papola, Gianni Rombolà, Nicoletta Sacchi, Valeria Miotti, Lia Mele, Benedetta Mazzi, Fabio Ciceri, Massimo Martino, Anna Paola Iori\",\"doi\":\"10.2450/BloodTransfus.790\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antibodies directed against donor-specific HLA allele(s)/antigen(s) (DSAs) represent a known risk factor for hematopoietic stem cell transplantation (HSCT) engraftment. Still, the overall management needs to be standardized.</p><p><strong>Material and methods: </strong>GITMO and AIBT ran a survey on DSAs in Italian Transplant Programs including mismatched HSCT performed between January 2014 and June 2017.</p><p><strong>Results: </strong>One-thousand-thirty-three patients were proposed for the study, 804 were evaluable. Overall, 355 (44%) were screened: 91/355 (25.6%) showed anti-HLA antibodies, 23 DSAs (6.5%). Female gender and at least 4 previous pregnancies showed an impact on alloimmunization. Eleven patients with DSAs underwent desensitization. In seven cases no desensitization was employed. An alternative donor was selected for five patients. Neutrophil and platelet engraftment were obtained in 93.6% and 86.6% of the whole population, respectively, and were statistically associated with the absence of anti-HLA antibodies, ABO match, a higher number of infused nucleated cells and lack of a-GvHD. In addition, significant factors for platelet engraftment were the use of leuco-depleted transfusions, HLA match, younger age of the patient. Graft failure (GF) was associated with bone marrow stem cell source, and a lower number of infused CD34+. The detection of antibodies directed against both HLA classes, donor and patient age, the hematologic and molecular remission at HSCT, HLA match, ANC and PLTS engraftment, full donor engraftment within 28 days after HSCT, early and late GF, grade>II a-GVHD showed an impact on OS.</p><p><strong>Discussion: </strong>Anti-HLA antibodies and DSAs were confirmed as risk factors affecting OS. DSAs were managed with various approaches resulting in stable engraftment in 81.9% of patients. Our study supports the clinical relevance of DSAs detection and management in mmHSCT. A standardized approach of DS is warranted.</p>\",\"PeriodicalId\":49260,\"journal\":{\"name\":\"Blood Transfusion\",\"volume\":\" \",\"pages\":\"176-185\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925252/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2450/BloodTransfus.790\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2450/BloodTransfus.790","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT.
Background: Antibodies directed against donor-specific HLA allele(s)/antigen(s) (DSAs) represent a known risk factor for hematopoietic stem cell transplantation (HSCT) engraftment. Still, the overall management needs to be standardized.
Material and methods: GITMO and AIBT ran a survey on DSAs in Italian Transplant Programs including mismatched HSCT performed between January 2014 and June 2017.
Results: One-thousand-thirty-three patients were proposed for the study, 804 were evaluable. Overall, 355 (44%) were screened: 91/355 (25.6%) showed anti-HLA antibodies, 23 DSAs (6.5%). Female gender and at least 4 previous pregnancies showed an impact on alloimmunization. Eleven patients with DSAs underwent desensitization. In seven cases no desensitization was employed. An alternative donor was selected for five patients. Neutrophil and platelet engraftment were obtained in 93.6% and 86.6% of the whole population, respectively, and were statistically associated with the absence of anti-HLA antibodies, ABO match, a higher number of infused nucleated cells and lack of a-GvHD. In addition, significant factors for platelet engraftment were the use of leuco-depleted transfusions, HLA match, younger age of the patient. Graft failure (GF) was associated with bone marrow stem cell source, and a lower number of infused CD34+. The detection of antibodies directed against both HLA classes, donor and patient age, the hematologic and molecular remission at HSCT, HLA match, ANC and PLTS engraftment, full donor engraftment within 28 days after HSCT, early and late GF, grade>II a-GVHD showed an impact on OS.
Discussion: Anti-HLA antibodies and DSAs were confirmed as risk factors affecting OS. DSAs were managed with various approaches resulting in stable engraftment in 81.9% of patients. Our study supports the clinical relevance of DSAs detection and management in mmHSCT. A standardized approach of DS is warranted.
期刊介绍：
Blood Transfusion welcomes international submissions of Original Articles, Review Articles, Case Reports and Letters on all the fields related to Transfusion Medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
